New 'Living Drug' tested for tough stomach cancers

This early-stage study is testing the safety of a new cell therapy called AB-201 for people with advanced HER2-positive stomach or gastroesophageal junction cancer who have already tried at least two standard treatments. Researchers will give patients a single infusion of specially modified immune cells designed to find and attack cancer. The main goal is to see if the treatment is safe and to find the right dose, while also checking for any early signs that it might help shrink tumors.